HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunogenicity of the Haemophilus influenzae type b capsular polysaccharide conjugate vaccine in children after systemic Haemophilus influenzae type b infections.

Abstract
We immunized 24 patients (mean age 15.2 +/- 9.3 months) with polyribosylribitol phosphate-diphtheria toxoid conjugate vaccine (PRP-D) 2 months after a systemic Haemophilus influenzae type b infection. Children less than 24 months of age were immunized twice. Serum was obtained for antibody to PRP before and 1 or 2 months after immunization. Three of five children greater than 24 months of age and three of six children 18 to 24 months of age developed greater than 1 microgram/ml of antibody after immunization, and geometric mean postimmunization levels were significantly greater than preimmunization levels for both groups. However, two children who failed to respond to conventional PRP vaccine did not respond as expected to one dose of PRP-D. For children 7 to 17 months of age, the geometric mean PRP antibody levels increased as follows: preimmunization, 0.05 micrograms/ml; after the first dose, 0.28 micrograms/ml (p = 0.003); and after the second dose, 3.39 micrograms/ml (p = 0.001). Of 13 children, 10 developed antibody values greater than 1.0 micrograms/ml. PRP conjugate vaccines are immunogenic in young children who have not developed protective PRP antibody levels after a systemic H. Influenzae type b infection.
AuthorsS L Kaplan, J M Zahradnik, E O Mason Jr, C M Dukes
JournalThe Journal of pediatrics (J Pediatr) Vol. 113 Issue 2 Pg. 272-7 (Aug 1988) ISSN: 0022-3476 [Print] United States
PMID3260943 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Bacterial
  • Bacterial Vaccines
  • Diphtheria Toxoid
  • Haemophilus Vaccines
  • Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate
Topics
  • Antibodies, Bacterial (biosynthesis)
  • Bacterial Vaccines (administration & dosage, therapeutic use)
  • Child, Preschool
  • Diphtheria Toxoid (administration & dosage, therapeutic use)
  • Haemophilus Infections (immunology)
  • Haemophilus Vaccines
  • Haemophilus influenzae (immunology)
  • Humans
  • Immunization
  • Infant
  • Time Factors
  • Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: